- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00716820
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Outcome Survey Of Specific Use Of 12.5 Mg Sutent Capsule Against Gastrointestinal Stromal Tumor: Implementation Guidelines.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the surveillance.
Exclusion Criteria:
Patients not administered SUNITINIB MALATE(Sutent).
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SUNITINIB MALATE
Patients taking Sutent.
|
SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. "The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated. The dosage may be decreased according to the patient's clinical condition."
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Adverse Events
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
|
MAX 2 Years
|
Objective Response Rate
Time Frame: MAX 2 Years
|
Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).
The result was presented along with the corresponding exact 2-sided 95% confidence interval (CI).
|
MAX 2 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rates by KIT Expression Status
Time Frame: MAX 2 Years
|
Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST.
Objective response rates by KIT expression status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs.
|
MAX 2 Years
|
Objective Response Rates by c-Kit Mutation Status
Time Frame: MAX 2 Years
|
Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST.
Objective response rates by c-kit mutation status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs.
|
MAX 2 Years
|
Objective Response Rates by Platelet - Derived Growth Factor Receptor Alpha (PDGFRα) Mutation Status
Time Frame: MAX 2 Years
|
Percentage of participants with objective response based assessment of CR or confirmed PR according to RECIST.
Objective response rates by PDGFRα mutation status were calculated according to RECIST and were presented along with the corresponding exact 2-sided 95% CIs.
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events in Elderly Population
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
Elderly population was defined as the participants who aged 65 or older.
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events Who Had Hepatic Impairment
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
Hepatic impairment referred not to transient laboratory test value abnormalities, but to the events that were clinically noteworthy and required follow-up.
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events Who Had Renal Impairment
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
Renal impairment referred not to transient laboratory test value abnormalities, but to the events that were clinically noteworthy and required follow-up.
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events Who Used Concomitant Cytochrome P450 3A4 (CYP3A4) Inhibitors
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
A total of 38 drugs including tofisopam, bromocriptin mesilate, and fluvoxamine maleate were defined as CYP3A4 inhibitors.
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events Who Were Under Long-Term Treatment
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
The long-term treatment was defined as the treatment continued more than 24 weeks.
|
MAX 2 Years
|
Numbers of Participants With Treatment-Related Adverse Events Corresponded to Items for Priority Investigation
Time Frame: MAX 2 Years
|
The following adverse events were defined as items for priority investigation : (1) lung disorder including interstitial pneumonia, (2) bone marrow depression including platelets decreased, white blood cell decreased, and anaemia, (3) haemorrhage including those due to tumor degeneration or shrinkage, (4) cardiac function disturbance including QT interval prolonged and left ventricular ejection fraction decreased, (5) dysfunction adrenal, (6) pancreatic dysfunction including lipase increased, (7) thyroid function decreased, (8) cutaneous symptoms (hand and foot syndrome), (9) serious infections, (10) rhabdomyolysis, myopathy, and (11) reversible posterior leukoencephalopathy syndrome (RPLS).
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
|
MAX 2 Years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Related Serious Adverse Events
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
A treatmen-trelated serious adverse event was a treatment-related adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; lifethreatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events Unexpected From Japanese Package Insert
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
Expectedness of the adverse event was determined according to the Japanese package insert.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
|
MAX 2 Years
|
Number of Participants With Treatment-Related Adverse Events Grade 3 or Higher in Common Toxicity Criteria for Adverse Events (CTCAE)
Time Frame: MAX 2 Years
|
A treatment-related adverse event was any untoward medical occurrence attributed to sunitinib malate in a participant who received sunitinib malate.
Relatedness to sunitinib malate was assessed by the investigator and sponsor (Pfizer Japan Inc.).
The severity for each adverse event was assessed according to CTCAE as follows: grade 3, severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, or disabling; grade 4, life-threatening consequences or urgent intervention indicated; grade 5, death related to adverse event.
|
MAX 2 Years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Neoplasms, Connective Tissue
- Gastrointestinal Stromal Tumors
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- A6181175
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Stromal Tumors
-
Washington University School of MedicineNorthwestern UniversityCompletedGastrointestinal Stromal Cell Tumors | Foregut Subepithelial LesionsUnited States
-
Centre Leon BerardGustave Roussy, Cancer Campus, Grand ParisCompletedSarcoma | Gastro-intestinal Stromal Tumors (GIST)France
-
AB ScienceCompletedGastro Intestinal Stromal TumorFrance
-
Centre Leon BerardRecruiting
-
Institut BergoniéFrench Sarcoma GroupRecruitingGastro Intestinal Stromal TumorFrance
-
University Medical Center GroningenDutch Cancer SocietyRecruitingGastro-intestinal Stromal TumorNetherlands
-
AB ScienceCompletedGastro-intestinal Stromal TumoursFrance
-
National University Hospital, SingaporeUnknownAsian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With ImatinibSingapore
-
Blueprint Medicines CorporationCompletedGastrointestinal Stromal Tumors (GIST) | Other Relapsed or Refractory Solid TumorsUnited States, United Kingdom, France, Korea, Republic of, Belgium, Germany, Italy, Netherlands, Poland, Spain
-
Institut BergoniéCompletedAdvanced Gastrointestinal Stromal TumorsFrance
Clinical Trials on SUNITINIB MALATE
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedRenal Cell Carcinoma | Gastrointestinal Stromal Tumors | Pancreatic Neuroendocrine TumorChina
-
PfizerCompletedCarcinoma, Renal CellUnited States
-
Icahn School of Medicine at Mount SinaiPfizerCompleted
-
Sidney Kimmel Cancer Center at Thomas Jefferson...PfizerActive, not recruitingSunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaCiliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney CarcinomaUnited States
-
Tony Bekaii-SaabPfizerCompletedEsophageal CancerUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States